USFDA grants Glenmark permission to market oral contraceptive pill
The approved drug is the generic equivalent of Teva's Seasonale tablet, which achieved annual sales of approximately $53.7 million for the 12 month period ending April 2015
Seasonale is indicated for the prevention of pregnancy in women who chose to use oral contraceptives as a method of contraception, said Glenmark in a press release. According to IMS Health, Seasonale achieved annual sales of approximately $53.7 million for the 12 month period ending April 2015.
With this, Glenmark has received approvals for 12 oral contraceptive and two extended-cylce oral contraceptive from the US drug regulator.